摘要
目的 :探讨脂肝泰胶囊治疗高脂血症性脂肪肝的作用机制。方法 :采用高脂饮食喂饲大鼠复制脂肪肝模型 ,实验分组为模型组、脂肝泰高剂量组、脂肝泰低剂量组、东宝肝泰对照组和正常对照组。以高、低剂量脂肝泰和东宝肝泰进行干预 ,然后测定各组大鼠血浆胰高血糖素和血清胰岛素、游离脂肪酸及肝组织中游离脂肪酸的含量。结果 :模型组大鼠血浆胰高血糖素、血清和肝组织中游离脂肪酸的含量均较正常组明显升高 (P <0 .0 5或 P <0 .0 1) ;血清胰岛素的含量较正常组明显降低 (P <0 .0 1)。与模型组比较 ,各治疗组大鼠血浆胰高血糖素、血清和肝组织中游离脂肪酸的含量均明显降低 (P<0 .0 5或 P<0 .0 1) ,脂低组各项指标的含量均低于对照组 (P<0 .0 5 ) ;各治疗组大鼠血清胰岛素的含量均明显升高 (P <0 .0 1) ,高、低剂量组的含量高于对照组 (P <0 .0 5 ) ;结论 :脂肝泰胶囊可通过降低胰高血糖素。
Objective:To explore the possible role of zhigantai(ZHGT)capsule in the therapy of fatty liver with hyperlipidemia Methods:The animal models with high fat diet were divided into model group,high dose group,low dose group,dongbao gantai(DBGT)group as well as control group and normal control group at random All the treatment groups were intervened by its own medicine,then detected glucagon contents in plasma,serum insulin contents and free fatty acid(FFA)contents in serum,hepatic tissue Results:The glucagon contents in plasma and FFA contents in serum,hepatic tissue of model group were increased significantly(P<0 05 or P<0 01) The serum insulin contents were reduced remarkably than normal control group(P<0 01) Compared with model group,glucagon contents in plasma and FFA contents in serum,hepatic tissue of all the treatment groups were reduced remarkably(P<0 05 or P<0 01) The content of all the guideline in low dose group was lower than DBGT group(P<0 05) The serum insulin contents of all the treatment groups were increased significantly(P<0 01) The contents of high dose group and low dose group were higher than DBGT group(P<0 05) Conclusions:By reducing the content of glucagons and increasing the insulin and FFA contents,ZHGT capsule had the effect of resisting fatty liver
出处
《山东中医杂志》
北大核心
2002年第11期679-682,共4页
Shandong Journal of Traditional Chinese Medicine
基金
河北省科技厅攻关计划项目 (课题号 :0 2 2 7613 5 )
